You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Title |
Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas
|
|---|---|
| Published in |
Cancer Treatment Reviews, May 2015
|
| DOI | 10.1016/j.ctrv.2015.05.007 |
| Pubmed ID | |
| Authors |
D. Pérez-Callejo, J. González-Rincón, A. Sánchez, M. Provencio, M. Sánchez-Beato |
| Abstract |
Anti-CD20 monoclonal antibodies (mAbs) have improved patient's survival with Non-Hodgkin Lymphoma, when combined with chemotherapy. Several mechanisms of action have been reported, including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and induction of apoptosis. Despite the large amount of studies and published data, the role each mechanism played in vivo is not fully understood. Furthermore, the reason why a significant percentage of patients are refractory or resistant remains unknown. Several activated intracellular signaling pathways have been implicated in the mechanisms of resistance of rituximab. In the present manuscript, we review those mechanisms and new anti-CD20 mAbs, as well as the efforts being accomplished to overcome it, focusing on new drugs targeting pathways implicated in resistance to rituximab. |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 1% |
| Unknown | 79 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 16 | 20% |
| Student > Ph. D. Student | 13 | 16% |
| Researcher | 13 | 16% |
| Student > Master | 12 | 15% |
| Other | 5 | 6% |
| Other | 10 | 13% |
| Unknown | 11 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 25 | 31% |
| Medicine and Dentistry | 16 | 20% |
| Biochemistry, Genetics and Molecular Biology | 10 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 8% |
| Chemistry | 3 | 4% |
| Other | 8 | 10% |
| Unknown | 12 | 15% |